BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Eppendorf opens new site in Singapore

August 1, 2022 | News

Targeted strengthening of customer focus with high-tech laboratory for pipette calibration and extensive range of high-quality laboratory services



The globally active Eppendorf Group continues its growth track in Asia in a targeted manner and has opened a new site in Singapore. The new subsidiary is located in the heart of Singapore's modern Biopolis science center and offers attractive office workplaces for sales and service activities, a modern pipette calibration laboratory and a demo laboratory. Here high-quality laboratory services, which include extensive customer training and maintenance offerings, are provided.

"Asia, with the market regions China and Asia, Pacific, Africa (APA), is an extremely important market for the Eppendorf Group, already accounting for around one third of our total revenue," says Eva van Pelt, Co-CEO of Eppendorf SE. "Singapore is a center of life sciences with a very large growth potential. We are therefore pleased to now be part of this dynamic life science ecosystem with our new location and to be able to further intensify and expand our existing customer relationships."

Eppendorf's new site is located within Singapore's Biopolis science center, which focuses on biomedical research projects and enables close cooperation between public and private scientific institutions. In addition to modern office space, there is a service center for all Eppendorf equipment, offering repairs, calibrations and validations, as well as a state-of-the-art calibration laboratory for pipettes. The additional purpose-built Bioprocess Center provides scientific and technical support to customers and partners throughout the Asia-Pacific region.

"From Singapore, we can now even better support our customers in scientific, research, healthcare, pharmaceutical and industrial sectors and offer them the relevant products and services within immediate reach," emphasizes Eva van Pelt. "With this investment, we will be able to participate even better in the growth of the life science industry in Asia and continue our strategic approach for even more customer centricity in Asia."